Hans Klingemann

Treatment of patients with advanced cancer with the natural killer cell line NK-92

Torsten Tonn, Dirk Schwabe, Hans Klingemann et al. · Cytotherapy · 2013 · 471 citations

Life Sciences, Immunology, Oncology +12

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

Sally Arai, Richard Meagher, Michelle L. Swearingen et al. · Cytotherapy · 2008 · 429 citations

Medicine, Immunology, Oncology +10

Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor

Kurt Schönfeld, Christiane Sahm, Congcong Zhang et al. · Molecular Therapy · 2014 · 344 citations · Full text

Life Sciences, Immunology, Oncology +17

Are natural killer cells superior CAR drivers?

Hans Klingemann · OncoImmunology · 2014 · 266 citations · Full text

Life Sciences, Immunology, Oncology +14

<scp>CD</scp>19‐<scp>CAR</scp> engineered <scp>NK</scp>‐92 cells are sufficient to overcome <scp>NK</scp> cell resistance in B‐cell malignancies

A Romański, Christoph Uherek, Gesine Bug et al. · Journal of Cellular and Molecular Medicine · 2016 · 224 citations · Full text

Life Sciences, Immunology, Oncology +17